Anthem Biosciences Limited (NSE: ANTHEM) stock cleared its 6M resistance trendline and is up 5% intraday at ₹896.8.
Biocon Limited (BIOCON) reports Q1 FY27 results with a 9% revenue increase, driven by strong biosimilars performance.
Biocon Limited (BIOCON) reports a 9% rise in total income to Rs 4,391 Cr for Q1 FY27, driven by strong Biopharma growth.
Blue Jet Healthcare Limited (BLUEJET) has broken below its support line and is down 5% intraday at ₹593.9.
Biocon Limited (BIOCON) announces the U.S. launch of Yesafili™, a biosimilar to Regeneron’s Eylea® 2 mg, expanding access to eye treatment.
Concord Biotech Limited (CONCORDBIO) stock moves up 5% intraday, nearing resistance at ₹1419. The stock is 0.
Syngene International Limited (SYNGENE) reports Q1 FY27 revenue at Rs. 736 Cr, with Operating EBITDA at Rs. 91 Cr.
Concord Biotech Limited (NSE: CONCORDBIO) stock extends gains, moving up 5% intraday to ₹1331.0, despite the 6M trendline status being CONSOLIDATING UP.
Anthem Biosciences Limited (NSE: ANTHEM) stock price falls 5% intraday to ₹746.1, breaking below support in a sectoral breakdown..
Anthem Biosciences Limited (NSE: ANTHEM) announces investor presentation on July 21, 2026, highlighting strategic updates and financial performance.